Extended Data Fig. 7: Screening FDA approved drug library for BCAT2 inhibitor.
From: BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16
Sketch map for screening BCAT2 inhibitor from FDA proved library. (b) Repeat data of top 8 compounds from the first-round screen. n=3 biological independent experiments. (c) TEL inhibits human BCAT2 enzyme activity. OD of NADH changes was shown in left panel. BCAT protein was purified from E.Coli and incubated with TEL for 1h, followed by measuring enzyme activity. n=3 biological independent experiments. (d) Other compounds from Sartan catalogue have no effect on BCAT2 activity. n=3 biological independent experiments. (e) TEL inhibits mouse Bcat2 enzyme activity. OD of NADH changes was shown in left panel. NIH3T3 cells transfected with Flag-Bcat2 were treated with TEL for 24h, followed by IP Flag and measuring enzyme activity. n=3 biological independent experiments. Bars and error bars represent mean values and SDs, with biologically individual data points shown. P values are derived from unpaired, two-tailed t-test.
